Menu

Pipeline Overview*

PRODUCT1 Indication Pre-clinical Phase 1/2 Phase 3 Commercial
Talicia® H. pylori infection2
APPROVED BY U.S. FDA NOVEMBER 2019
MOVANTIK® Opioid induced constipation3
GLOBAL RIGHTS EXCLUDING EUROPE, CANADA, ISRAEL
Aemcolo® Travelers' Diarrhea4
U.S. EXCLUSIVE LICENSE
Donnatal® IBS and acute enterocolitis5
U.S. CO-PROMOTION
Mytesi® Non-infectious diarrhea in HIV/AIDS patients5
U.S. CO-PROMOTION
EnteraGam® Chronic diarrhea and loose stools7
U.S. EXCLUSIVE LICENSE
Esomeprazole Strontium DR Capsules GERD and other GI conditions6
U.S. COMMERCIALIZATION LICENSE
RHB-104 Crohn's disease
RHB-204 NTM infections
RHB-102
(Bekinda®)
Gastroenteritis & gastritis
IBS-D
RHB-106 Bowel cleanser
Opaganib
(Yeliva®)
Oncology indications and COVID-19
RHB-107
upamostat
Oncology/GI and COVID-19
Other
RIZAPORT®
(RHB-103)
Migraine
* Estimated timeline/indication in the pipeline is subject to changes in development plans and regulatory requirements/clarifications, including complementary /additional studies
1 Bekinda® (RHB-102) and Yeliva® (Opaganib) are proposed tradenames which are subject to FDA review and approval
2 Talicia® (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of H. pylori infection in adults. For full prescribing information see: here
3 Movantik® (naloxegol) is indicated for the treatment of opioid induced constipation (OIC) in adults with chronic non cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (e.g. weekly) opioid dosage escalation. For full prescribing information see: here
4 Aemcolo® (rifamycin) is indicated for the treatment of travelers diarrhea caused by noninvasive strains of Escherichia Coli  in adults. For full prescribing information see: here

Company Profile

RedHill Biopharma Ltd. (NASDAQ: RDHL) is a specialty biopharmaceutical company focused on gastrointestinal diseases.

Read more